GlassScriptPhysician profile
Cristian Breton
NPI 1881683647
$8,656.92
in general payments reported to CMS, 2019-2025
49 companies · $926 in 2025
The $926 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,194 · 2020: $609 · 2021: $1,839 · 2022: $1,073 · 2023: $1,160 · 2024: $856 · 2025: $926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,942.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,942.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,029.28 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $734.67 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $724.44 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $677.07 | 2019-2025 | Ubrelvy |
| Novo Nordisk INC | $537.72 | 2019-2025 | Wegovy |
| Janssen Pharmaceuticals, INC | $469.97 | 2019-2022 | |
| Glaxosmithkline, LLC. | $379.19 | 2019-2021 | |
| Pfizer INC. | $360.53 | 2019-2024 | |
| Corcept Therapeutics | $335.22 | 2021-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $310.73 | 2021-2024 | |
| Astellas Pharma US INC | $257.58 | 2019-2023 | Myrbetriq |
| Sanofi-Aventis U.S. LLC | $247.71 | 2019-2022 | |
| Abbott Laboratories | $243.86 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Amgen INC. | $231.17 | 2019-2025 | Repatha, Otezla, Otezla |
| Sumitomo Pharma America, INC. | $188.80 | 2023-2025 | Gemtesa |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $187.17 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $148.41 | 2019-2024 | |
| Exact Sciences Corporation | $143.60 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Esperion Therapeutics, INC. | $139.23 | 2020-2023 | Nexletol |
| Merck Sharp & Dohme LLC | $127.56 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $121.22 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Daiichi Sankyo INC. | $107.00 | 2020-2022 | |
| Medtronic, INC. | $102.65 | 2022-2023 | Minimed 780g, Minimed 770g |
| Sunovion Pharmaceuticals INC. | $95.11 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $68.59 | 2019 | |
| Insulet Corporation | $63.89 | 2021-2025 | Omnipod |
| E.R. Squibb & Sons, L.L.C. | $60.40 | 2019-2024 | Camzyos |
| Mannkind Corporation | $59.40 | 2022 | |
| Allergan, INC. | $46.90 | 2020 | |
| Radius Health, INC. | $45.95 | 2021 | |
| Horizon Therapeutics Plc | $42.00 | 2021-2022 | |
| Genentech USA, INC. | $41.19 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $39.59 | 2021 | |
| Eisai INC. | $35.44 | 2021 | |
| Shire North American Group INC | $33.33 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.12 | 2019-2022 | |
| Valeritas, INC. | $30.02 | 2019 | |
| Tandem Diabetes Care, INC. | $25.33 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Alexion Pharmaceuticals, INC. | $24.96 | 2022 | |
| Ibsa Pharma INC. | $21.81 | 2023 | Licart, Tirosint |
| Corium, LLC | $20.26 | 2023 | Adlarity |
| Ardelyx, INC. | $18.83 | 2024 | Ibsrela |
| Phadia US INC. | $17.78 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $15.38 | 2024 | Rexulti |
| Dexcom, INC. | $13.86 | 2023 | Dexcom G6 Transmitter |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cristian Breton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.